An analyst from Piper Sandler maintained a positive stance on Masimo Corp . (NASDAQ:), a medical technology company, reiterating an Overweight rating with a $165.00 price target. The analyst emphasized the potential for the company’s stock to rise further following a 30% increase over the past month. This uptick was attributed to a series of positive developments including a shareholder vote, management and board changes, a commitment to a strategic review of its Consumer division, and the reaffirmation of third-quarter guidance.
The analyst believes that the recent surge in Masimo’s share price is just the beginning of a more significant upward trend. The confidence stems from the expectation that the investment case for Masimo will become less risky and that the company will experience an earnings power inflection in 2025 and 2026. This anticipated growth is seen as potentially outpacing any other stock within Piper Sandler’s coverage universe, with current Street estimates not fully accounting for this upside.
Further bolstering the analyst’s outlook is the possibility of a “call option” that could emerge from upcoming litigation with Apple. While details on this matter were not provided, it is suggested that the outcome could have a favorable impact on Masimo’s stock. The analyst’s discussion on these topics was set to be elaborated during a call as part of Piper Sandler’s Bull vs. Bear debate series focused on the medical technology sector.
Masimo’s elevation to “top idea status” on Piper Sandler’s list reflects the firm’s increased conviction in the company’s prospects. The analyst’s commentary indicates a belief that the market has not yet fully recognized the potential for Masimo’s earnings to grow and for the stock to appreciate in value.
The company, known for its innovative non-invasive patient monitoring technologies, has been in the spotlight following its strategic moves and the anticipation of its third-quarter performance. Investors and stakeholders are likely to watch closely as Masimo navigates the upcoming quarter and the developments mentioned by the analyst.
Masimo Corp is maintaining its course amidst a flurry of developments. A key highlight is the company’s third-quarter non-GAAP financial guidance, projecting revenues between $495 million and $515 million, and earnings per share (EPS) forecast set at $0.81 to $0.86. The company is also in the midst of a significant leadership change, with former CEO Joe Kiani stepping down and Michelle Brennan stepping in as interim CEO.
In the legal sphere, Masimo is engaged in a trade secrets litigation against Apple Inc (NASDAQ:), with a bench trial set to start on November 5, 2024. Wells Fargo has reaffirmed its Overweight rating on Masimo shares, maintaining a price target of $160.00 despite these ongoing legal proceedings.
InvestingPro Insights
Recent data from InvestingPro provides additional context to the analyst’s optimistic outlook on Masimo Corp. (NASDAQ:MASI). The company’s market capitalization stands at $7.64 billion, reflecting its significant presence in the medical technology sector. Masimo’s stock has shown remarkable strength, with a 1-year price total return of 80.4% as of the latest data, aligning with the analyst’s observation of recent price appreciation.
InvestingPro Tips highlight that Masimo is trading near its 52-week high, with a price that is 92.87% of its highest point over the past year. This supports the analyst’s view that the stock has room for further growth. Additionally, the company’s net income is expected to grow this year, which could contribute to the anticipated earnings power inflection mentioned in the analyst report.
It’s worth noting that Masimo operates with a moderate level of debt and its liquid assets exceed short-term obligations, potentially providing financial flexibility as it pursues strategic initiatives. These factors may contribute to the reduced risk profile that the analyst anticipates.
Investors considering Masimo should be aware that InvestingPro offers 16 additional tips for this stock, providing a more comprehensive analysis for those seeking deeper insights into the company’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
